$0.41
5.30% yesterday
Nasdaq, Aug 12, 10:11 pm CET
ISIN
US09075X1081
Symbol
BDSX

Biodesix Inc Stock price

$0.41
+0.10 31.44% 1M
-0.53 56.28% 6M
-1.12 73.14% YTD
-1.20 74.47% 1Y
-2.20 84.25% 3Y
-12.40 96.79% 5Y
-12.40 96.79% 10Y
-12.40 96.79% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.02 5.30%

Key metrics

Basic
Market capitalization
$57.2m
Enterprise Value
$76.3m
Net debt
$19.1m
Cash
$17.6m
Shares outstanding
146.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
0.8 | 0.7
EV/Sales
1.0 | 0.9
EV/FCF
negative
P/B
5.2
Financial Health
Equity Ratio
21.5%
Return on Equity
-205.7%
ROCE
-44.4%
ROIC
-52.5%
Debt/Equity
3.3
Financials (TTM | estimate)
Revenue
$74.5m | $83.7m
EBITDA
$-26.6m | $-16.8m
EBIT
$-32.4m | $-30.0m
Net Income
$-40.4m | $-36.4m
Free Cash Flow
$-45.2m
Growth (TTM | estimate)
Revenue
35.8% | 17.3%
EBITDA
16.8% | 41.9%
EBIT
9.8% | 12.3%
Net Income
14.1% | 15.3%
Free Cash Flow
1.9%
Margin (TTM | estimate)
Gross
78.4%
EBITDA
-35.7% | -20.1%
EBIT
-43.5%
Net
-54.3% | -43.5%
Free Cash Flow
-60.8%
More
EPS
$-0.3
FCF per Share
$-0.3
Short interest
5.8%
Employees
217
Rev per Employee
$330.0k
Show more

Is Biodesix Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Biodesix Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Biodesix Inc forecast:

10x Buy
83%
2x Hold
17%

Analyst Opinions

12 Analysts have issued a Biodesix Inc forecast:

Buy
83%
Hold
17%

Financial data from Biodesix Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
74 74
36% 36%
100%
- Direct Costs 16 16
24% 24%
22%
58 58
40% 40%
78%
- Selling and Administrative Expenses 80 80
17% 17%
108%
- Research and Development Expense 10 10
18% 18%
14%
-27 -27
17% 17%
-36%
- Depreciation and Amortization 5.79 5.79
46% 46%
8%
EBIT (Operating Income) EBIT -32 -32
10% 10%
-43%
Net Profit -40 -40
14% 14%
-54%

In millions USD.

Don't miss a Thing! We will send you all news about Biodesix Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Biodesix Inc Stock News

Neutral
Seeking Alpha
3 days ago
Biodesix, Inc. (NASDAQ:BDSX ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Robin Harper Cowie - CFO, Secretary & Treasurer Scott Hutton - President, CEO & Director Conference Call Participants Alexander Davis Vukasin - Canaccord Genuity Corp., Research Division Andrew Frederick Brackmann - William Blair & Company L.L.C., Research Division Thomas Flaten - Lake ...
Neutral
GlobeNewsWire
5 days ago
Q2 2025 Revenue of $20.0 million, an increase of 12% over Q2 2024; Q2 2025 gross profit margin of 80%, a 150-basis point improvement from Q2 2024; Reiterating FY2025 Total Revenue Guidance of $80-85 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo.
Neutral
GlobeNewsWire
8 days ago
BOULDER, Colo., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, will present in a fireside chat and host in-person 1x1 investor meetings at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025.
More Biodesix Inc News

Company Profile

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. It offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer; and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It is a data-driven diagnostic solutions company with proprietary AI platform to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in lung disease. The firm offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. . The company was founded in 2005 and is headquartered in Boulder, CO.

Head office United States
CEO Scott Hutton
Employees 217
Founded 2005
Website www.biodesix.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today